 In-PharmaTechnologist.com | Samsung halts biosimilar rituximab trial on regulatory concerns In-PharmaTechnologist.com The JV formed through the deal is focused on developing biosimilar versions of marketed products which - evidently - included a version of Biogen's own product blockbuster, which is used to treat lymphomas, leukemias, transplant rejection, and some ... |
